FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2401311491> ?p ?o ?g. }

• W2401311491 endingPage "93" @default.
• W2401311491 startingPage "289" @default.
• W2401311491 abstract "To investigate the expression of multidrug resistance (MDR) gene-associated proteins (MRP) in gastric carcinoma, and their effects on the postoperative adjuvant chemotherapy and the prognosis of patients.The expressions of ToPo II, MRP, GST-pi in 99 patients with gastric carcinoma were detected by immunohistochemistry. The expression and its relationship to the pathological data were analyzed. The positive expression of MRP and GST-pi, and the negative expression of ToPo II were considered as risk factors. Patients were divided into two groups: a high risk drug-resistant group (2-3 risk factors) and the low risk drug-resistant group (0-1 risk factors). Postoperative recurrence, survival rate, and efficacy of adjuvant chemotherapy were compared between two groups.The positive rate of ToPo II was 74.7%, and the expression was associated with types and differentiation of the tumor. The positive rate of GST-pi was 49.5%, and the expression was related to the gender and the differentiation. The positive rate of MRP was 40.4%, and there was no relationship between the MRP expression and the pathological finding. There were no significant differences in the recurrence, time to recurrence, and the 5-year survival rate between the positive and negative group of the three proteins (P>0.05). Recurrence was found in 25 cases(55.6%) in the high risk drug-resistant group and the mean time to recurrence was (15.2+/-8.1) months. The time to recurrence was shorter in the low risk drug-resistant group [(21.3+/-11.1) months, P<0.05] , but there was no significant difference in the recurrence rate between two groups (P>0.05). The 5-year survival rate of the high risk drug-resistant group and the low risk drug-resistant group was 44.4% and 55.6% (P>0.05). The 5-year survival rates of patients with or without chemotherapy in the high risk drug-resistant group were 45.8% and 42.9% (P>0.05). The 5-year survival rates of patients with or without chemotherapy in the low risk drug-resistant group were 70.4% and 40.7%. The survival rate of patients with chemotherapy was higher than that of the patients without chemotherapy (P<0.05).The expression of ToPo II, MRP and GST-pi is associated with the efficacy of postoperative adjuvant chemotherapy. Chemotherapy appears to be more beneficial to patients with low risk drug-resistance." @default.
• W2401311491 created "2016-06-24" @default.
• W2401311491 creator A5025912163 @default.
• W2401311491 creator A5033222289 @default.
• W2401311491 creator A5033251954 @default.
• W2401311491 creator A5036102958 @default.
• W2401311491 creator A5060655025 @default.
• W2401311491 creator A5078000842 @default.
• W2401311491 creator A5083521524 @default.
• W2401311491 creator A5091758507 @default.
• W2401311491 date "2010-04-01" @default.
• W2401311491 modified "2023-09-24" @default.
• W2401311491 title "[Significance of multidrug resistance gene-associated proteins in the postoperative adjuvant chemotherapy for gastric carcinoma and the prognosis]." @default.
• W2401311491 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20422488" @default.
• W2401311491 hasPublicationYear "2010" @default.
• W2401311491 type Work @default.
• W2401311491 sameAs 2401311491 @default.
• W2401311491 citedByCount "2" @default.
• W2401311491 countsByYear W24013114912015 @default.
• W2401311491 countsByYear W24013114912016 @default.
• W2401311491 crossrefType "journal-article" @default.
• W2401311491 hasAuthorship W2401311491A5025912163 @default.
• W2401311491 hasAuthorship W2401311491A5033222289 @default.
• W2401311491 hasAuthorship W2401311491A5033251954 @default.
• W2401311491 hasAuthorship W2401311491A5036102958 @default.
• W2401311491 hasAuthorship W2401311491A5060655025 @default.
• W2401311491 hasAuthorship W2401311491A5078000842 @default.
• W2401311491 hasAuthorship W2401311491A5083521524 @default.
• W2401311491 hasAuthorship W2401311491A5091758507 @default.
• W2401311491 hasConcept C114851261 @default.
• W2401311491 hasConcept C121608353 @default.
• W2401311491 hasConcept C126322002 @default.
• W2401311491 hasConcept C133936738 @default.
• W2401311491 hasConcept C143998085 @default.
• W2401311491 hasConcept C204232928 @default.
• W2401311491 hasConcept C207886595 @default.
• W2401311491 hasConcept C2776283816 @default.
• W2401311491 hasConcept C2776694085 @default.
• W2401311491 hasConcept C2777546739 @default.
• W2401311491 hasConcept C2777863537 @default.
• W2401311491 hasConcept C2993220764 @default.
• W2401311491 hasConcept C3018227240 @default.
• W2401311491 hasConcept C50440223 @default.
• W2401311491 hasConcept C530470458 @default.
• W2401311491 hasConcept C71924100 @default.
• W2401311491 hasConcept C86803240 @default.
• W2401311491 hasConcept C89423630 @default.
• W2401311491 hasConcept C90924648 @default.
• W2401311491 hasConceptScore W2401311491C114851261 @default.
• W2401311491 hasConceptScore W2401311491C121608353 @default.
• W2401311491 hasConceptScore W2401311491C126322002 @default.
• W2401311491 hasConceptScore W2401311491C133936738 @default.
• W2401311491 hasConceptScore W2401311491C143998085 @default.
• W2401311491 hasConceptScore W2401311491C204232928 @default.
• W2401311491 hasConceptScore W2401311491C207886595 @default.
• W2401311491 hasConceptScore W2401311491C2776283816 @default.
• W2401311491 hasConceptScore W2401311491C2776694085 @default.
• W2401311491 hasConceptScore W2401311491C2777546739 @default.
• W2401311491 hasConceptScore W2401311491C2777863537 @default.
• W2401311491 hasConceptScore W2401311491C2993220764 @default.
• W2401311491 hasConceptScore W2401311491C3018227240 @default.
• W2401311491 hasConceptScore W2401311491C50440223 @default.
• W2401311491 hasConceptScore W2401311491C530470458 @default.
• W2401311491 hasConceptScore W2401311491C71924100 @default.
• W2401311491 hasConceptScore W2401311491C86803240 @default.
• W2401311491 hasConceptScore W2401311491C89423630 @default.
• W2401311491 hasConceptScore W2401311491C90924648 @default.
• W2401311491 hasIssue "4" @default.
• W2401311491 hasLocation W24013114911 @default.
• W2401311491 hasOpenAccess W2401311491 @default.
• W2401311491 hasPrimaryLocation W24013114911 @default.
• W2401311491 hasRelatedWork W121672310 @default.
• W2401311491 hasRelatedWork W1614525454 @default.
• W2401311491 hasRelatedWork W2047578212 @default.
• W2401311491 hasRelatedWork W2049870521 @default.
• W2401311491 hasRelatedWork W2148843619 @default.
• W2401311491 hasRelatedWork W2233872369 @default.
• W2401311491 hasRelatedWork W2248894402 @default.
• W2401311491 hasRelatedWork W2255092253 @default.
• W2401311491 hasRelatedWork W2269222177 @default.
• W2401311491 hasRelatedWork W2352535670 @default.
• W2401311491 hasRelatedWork W2355031083 @default.
• W2401311491 hasRelatedWork W2364377444 @default.
• W2401311491 hasRelatedWork W2381345080 @default.
• W2401311491 hasRelatedWork W2389054451 @default.
• W2401311491 hasRelatedWork W2391910948 @default.
• W2401311491 hasRelatedWork W2923433677 @default.
• W2401311491 hasRelatedWork W3121022084 @default.
• W2401311491 hasRelatedWork W3153079849 @default.
• W2401311491 hasRelatedWork W3186715737 @default.
• W2401311491 hasRelatedWork W50240922 @default.
• W2401311491 hasVolume "13" @default.
• W2401311491 isParatext "false" @default.
• W2401311491 isRetracted "false" @default.
• W2401311491 magId "2401311491" @default.
• W2401311491 workType "article" @default.